Weber Darin J.

SEC source: 0001193125-26-086728 · ownership.xml · derivative · entry 1

Weber Darin J. · CIK 0001936228 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Class A Common Stock · 400,000 shares

Expires 2036-03-01

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2026.

SEC source: 0000950170-25-094797 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported sale of stock occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 15, 2025.

SEC source: 0000950170-25-032251 · ownership.xml · derivative · entry 1

Weber Darin J. · CIK 0001936228 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 450,000

Underlying: Class A Ordinary Shares · 450,000 shares

Expires 2035-03-01

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2025.

SEC source: 0000950170-24-108438 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,480

F1 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

SEC source: 0000950170-24-087273 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,892

F1 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.51, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-075563 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,718

F1 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.68 to $2.99, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-063281 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 137,956

F1 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.74 to $4.44, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-046887 · ownership.xml · nonDerivative · entry 2

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 155,194

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.53, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.direct: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

SEC source: 0000950170-24-046887 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 171,632

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.55, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.direct: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

SEC source: 0000950170-24-045248 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 172,432

F1 · ownership.direct: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

SEC source: 0000950170-24-044836 · ownership.xml · nonDerivative · entry 2

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 189,670

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.77, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.direct: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

SEC source: 0000950170-24-044836 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 273,773

F1 · ownership.direct: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

SEC source: 0000950170-24-025912 · ownership.xml · derivative · entry 2

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,264

Underlying: Class A Ordinary Shares · 117,264 shares

Expires 2034-03-01

F2 · derivative.exercise_date: The option vests 50% on the 1st anniversary of March 1, 2024 and the remaining 50% vests in substantially equal monthly installments for 12 months thereafter.

SEC source: 0000950170-24-025912 · ownership.xml · derivative · entry 1

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Class A Ordinary Shares · 225,000 shares

Expires 2034-03-01

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2024.

SEC source: 0000950170-24-011718 · ownership.xml · derivative · entry 3

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 402,283

Underlying: Class A Ordinary Shares · 137,073 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for Class A Ordinary Shares on a one-for-one basis.

F3 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

F3 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

SEC source: 0000950170-24-011718 · ownership.xml · derivative · entry 2

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 402,283

Underlying: Class A Ordinary Shares · 137,073 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for Class A Ordinary Shares on a one-for-one basis.

F2 · derivative.exercise_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

F2 · derivative.expiration_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

SEC source: 0000950170-24-011718 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 274,073

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-23-045159 · ownership.xml · derivative · entry 3

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 539,356

Underlying: Class A Ordinary Shares · 137,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for Class A Ordinary Shares on a one-for-one basis. On August 25, 2023, the reporting person provided ProKidney Corp. (the "Issuer") with notice of exchange, which exchange will be settled 60 days following the closing of the exchange period under the terms of the Exchange Agreement.

F3 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

F3 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

SEC source: 0000950170-23-045159 · ownership.xml · derivative · entry 2

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 539,356

Underlying: Class A Ordinary Shares · 137,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for Class A Ordinary Shares on a one-for-one basis. On August 25, 2023, the reporting person provided ProKidney Corp. (the "Issuer") with notice of exchange, which exchange will be settled 60 days following the closing of the exchange period under the terms of the Exchange Agreement.

F2 · derivative.exercise_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

F2 · derivative.expiration_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

SEC source: 0000950170-23-045159 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-003719 · doc4.xml · derivative · entry 1

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Class A Ordinary Shares · 250,000 shares

Expires 2033-01-16

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on January 16, 2023.

SEC source: 0001209191-22-054435 · doc4.xml · derivative · entry 1

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 418,076

Underlying: Class A Ordinary Shares · 418,076 shares

Expires 2032-10-20

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on October 19, 2022.

SEC source: 0000950103-22-012378 · dp177014_4-weber.xml · derivative · entry 2

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 676,356

Underlying: Class A Ordinary Shares · 676,356 shares

Expires not disclosed

F3 · security: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis.

F3 · derivative.exercise_price: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis.

F4 · derivative.exercise_price: These 199,770 Common Units and 476,586 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire.

F4 · derivative.exercise_date: These 199,770 Common Units and 476,586 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire.

F4 · derivative.expiration_date: These 199,770 Common Units and 476,586 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire.

SEC source: 0000950103-22-012378 · dp177014_4-weber.xml · derivative · entry 1

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 676,356

Underlying: Class A Ordinary Shares · 676,356 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Class B Ordinary Share has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP ("ProKidney") (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis.

F2 · derivative.exercise_price: These 199,770 Class B Ordinary Shares and 476,586 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire.

F2 · derivative.exercise_date: These 199,770 Class B Ordinary Shares and 476,586 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire.

F2 · derivative.expiration_date: These 199,770 Class B Ordinary Shares and 476,586 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire.